Public Employees Retirement Association of Colorado lifted its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 1,207.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 381,590 shares of the biopharmaceutical company’s stock after buying an additional 352,413 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Nektar Therapeutics were worth $22,789,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Oppenheimer Asset Management Inc. bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth about $129,000. Mark Sheptoff Financial Planning LLC increased its holdings in shares of Nektar Therapeutics by 79.4% in the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,700 shares during the last quarter. Flinton Capital Management LLC increased its holdings in shares of Nektar Therapeutics by 75.7% in the 2nd quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 3,392 shares during the last quarter. SeaCrest Wealth Management LLC bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth about $200,000. Finally, Kovack Advisors Inc. bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth about $240,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Nektar Therapeutics (NKTR) opened at $82.44 on Tuesday. The company has a market cap of $13,857.16, a PE ratio of -114.50 and a beta of 2.04. Nektar Therapeutics has a fifty-two week low of $12.50 and a fifty-two week high of $99.02. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The firm’s revenue was up 321.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS. equities analysts predict that Nektar Therapeutics will post -0.76 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and issued a $80.00 target price (up from $50.00) on shares of Nektar Therapeutics in a report on Wednesday, January 10th. Mizuho restated a “buy” rating and issued a $45.00 target price (up from $30.00) on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Jefferies Group restated a “buy” rating and issued a $35.00 target price on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $44.00 target price on shares of Nektar Therapeutics in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. Nektar Therapeutics has an average rating of “Buy” and an average price target of $46.17.

In related news, COO John Nicholson sold 15,910 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $37.78, for a total transaction of $601,079.80. Following the transaction, the chief operating officer now directly owns 249,066 shares in the company, valued at approximately $9,409,713.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Stephen K. Doberstein sold 396,323 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the transaction, the senior vice president now owns 52,016 shares in the company, valued at $1,508,464. The disclosure for this sale can be found here. Insiders have sold a total of 608,899 shares of company stock worth $24,813,370 over the last quarter. 5.44% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Public Employees Retirement Association of Colorado Boosts Stake in Nektar Therapeutics (NKTR)” was published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/public-employees-retirement-association-of-colorado-boosts-stake-in-nektar-therapeutics-nktr/1848450.html.

Nektar Therapeutics Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.